Literature DB >> 16873274

Distinct domains of the influenza a virus M2 protein cytoplasmic tail mediate binding to the M1 protein and facilitate infectious virus production.

Matthew F McCown1, Andrew Pekosz.   

Abstract

The cytoplasmic tail of the influenza A virus M2 protein is highly conserved among influenza A virus isolates. The cytoplasmic tail appears to be dispensable with respect to the ion channel activity associated with the protein but important for virus morphology and the production of infectious virus particles. Using reverse genetics and transcomplementation assays, we demonstrate that the M2 protein cytoplasmic tail is a crucial mediator of infectious virus production. Truncations of the M2 cytoplasmic tail result in a drastic decrease in infectious virus titers, a reduction in the amount of packaged viral RNA, a decrease in budding events, and a reduction in budding efficiency. The M1 protein binds to the M2 cytoplasmic tail, but the M1 binding site is distinct from the sequences that affect infectious virus particle formation. Influenza A virus strains A/Udorn/72 and A/WSN/33 differ in their requirements for M2 cytoplasmic tail sequences, and this requirement maps to the M1 protein. We conclude that the M2 protein is required for the formation of infectious virus particles, implicating the protein as important for influenza A virus assembly in addition to its well-documented role during virus entry and uncoating.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16873274      PMCID: PMC1563831          DOI: 10.1128/JVI.00627-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  82 in total

1.  The M2 protein of influenza A virus is acylated.

Authors:  M Veit; H D Klenk; A Kendal; R Rott
Journal:  J Gen Virol       Date:  1991-06       Impact factor: 3.891

2.  Isolation of matrix protein M1 from influenza viruses by acid-dependent extraction with nonionic detergent.

Authors:  O P Zhirnov
Journal:  Virology       Date:  1992-01       Impact factor: 3.616

3.  Nuclear transport of influenza virus ribonucleoproteins: the viral matrix protein (M1) promotes export and inhibits import.

Authors:  K Martin; A Helenius
Journal:  Cell       Date:  1991-10-04       Impact factor: 41.582

4.  Transport of incoming influenza virus nucleocapsids into the nucleus.

Authors:  K Martin; A Helenius
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

5.  Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line.

Authors:  J P Morgenstern; H Land
Journal:  Nucleic Acids Res       Date:  1990-06-25       Impact factor: 16.971

6.  Palmitoylation of the influenza A virus M2 protein.

Authors:  R J Sugrue; R B Belshe; A J Hay
Journal:  Virology       Date:  1990-11       Impact factor: 3.616

7.  Amantadine selection of a mutant influenza virus containing an acid-stable hemagglutinin glycoprotein: evidence for virus-specific regulation of the pH of glycoprotein transport vesicles.

Authors:  D A Steinhauer; S A Wharton; J J Skehel; D C Wiley; A J Hay
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

8.  Influenza virus M2 protein has ion channel activity.

Authors:  L H Pinto; L J Holsinger; R A Lamb
Journal:  Cell       Date:  1992-05-01       Impact factor: 41.582

9.  Specific structural alteration of the influenza haemagglutinin by amantadine.

Authors:  R J Sugrue; G Bahadur; M C Zambon; M Hall-Smith; A R Douglas; A J Hay
Journal:  EMBO J       Date:  1990-11       Impact factor: 11.598

10.  The GAG precursor of simian immunodeficiency virus assembles into virus-like particles.

Authors:  M Delchambre; D Gheysen; D Thines; C Thiriart; E Jacobs; E Verdin; M Horth; A Burny; F Bex
Journal:  EMBO J       Date:  1989-09       Impact factor: 11.598

View more
  103 in total

Review 1.  Influenza M2 proton channels.

Authors:  Rafal M Pielak; James J Chou
Journal:  Biochim Biophys Acta       Date:  2010-05-06

2.  An M2 cytoplasmic tail mutant as a live attenuated influenza vaccine against pandemic (H1N1) 2009 influenza virus.

Authors:  Yasuko Hatta; Masato Hatta; Pamuk Bilsel; Gabriele Neumann; Yoshihiro Kawaoka
Journal:  Vaccine       Date:  2011-01-25       Impact factor: 3.641

Review 3.  Novel vaccines against influenza viruses.

Authors:  S M Kang; J M Song; R W Compans
Journal:  Virus Res       Date:  2011-10-01       Impact factor: 3.303

Review 4.  Influenza A viruses: why focusing on M2e-based universal vaccines.

Authors:  Seyyed Mahmoud Ebrahimi; Majid Tebianian
Journal:  Virus Genes       Date:  2010-11-17       Impact factor: 2.332

5.  Role of the CM2 protein in the influenza C virus replication cycle.

Authors:  Takatoshi Furukawa; Yasushi Muraki; Takeshi Noda; Emi Takashita; Ri Sho; Kanetsu Sugawara; Yoko Matsuzaki; Yoshitaka Shimotai; Seiji Hongo
Journal:  J Virol       Date:  2010-11-24       Impact factor: 5.103

Review 6.  Flu channel drug resistance: a tale of two sites.

Authors:  Rafal M Pielak; James J Chou
Journal:  Protein Cell       Date:  2010-02-23       Impact factor: 14.870

7.  Intrinsic cytoskeleton-dependent clustering of influenza virus M2 protein with hemagglutinin assessed by FLIM-FRET.

Authors:  Bastian Thaa; Andreas Herrmann; Michael Veit
Journal:  J Virol       Date:  2010-09-29       Impact factor: 5.103

8.  The Influenza M2 Ectodomain Regulates the Conformational Equilibria of the Transmembrane Proton Channel: Insights from Solid-State Nuclear Magnetic Resonance.

Authors:  Byungsu Kwon; Mei Hong
Journal:  Biochemistry       Date:  2016-09-12       Impact factor: 3.162

Review 9.  Viral membrane scission.

Authors:  Jeremy S Rossman; Robert A Lamb
Journal:  Annu Rev Cell Dev Biol       Date:  2013-05-31       Impact factor: 13.827

10.  Cytoplasmic domain of influenza B virus BM2 protein plays critical roles in production of infectious virus.

Authors:  Masaki Imai; Kazunori Kawasaki; Takato Odagiri
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.